Invention Grant
- Patent Title: Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation
-
Application No.: US15593534Application Date: 2017-05-12
-
Publication No.: US10047103B2Publication Date: 2018-08-14
- Inventor: Jacques Banville , Roger Remillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dube , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
- Applicant: BRISTOL-MYERS SQUIBB COMPANY , Universite De Montreal
- Applicant Address: US NJ Princeton CA Montreal
- Assignee: Bristol-Myers Squibb Company,Universite de Montreal
- Current Assignee: Bristol-Myers Squibb Company,Universite de Montreal
- Current Assignee Address: US NJ Princeton CA Montreal
- Agency: Hoffman & Baron, LLP
- Main IPC: C07D513/04
- IPC: C07D513/04 ; C07D487/04 ; C07D519/00 ; A61K45/06 ; A61K31/433 ; A61K31/4439 ; A61K31/454 ; A61K31/496 ; A61K31/497 ; A61K31/5025 ; A61K31/5377 ; A61K31/541 ; A61K31/553 ; A61K31/435 ; A61K31/5386 ; A61K31/55 ; A61K51/04 ; C07B59/00

Abstract:
The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
Public/Granted literature
Information query